FARESTON® has been shown to be a generally well-tolerated and effective therapy for metastatic
breast cancer in postmenopausal women with ER-positive or ER-unknown tumors.
FARESTON® has been used for over 20 years to help women with metastatic breast cancer. In clinical trials, FARESTON® helped to slow the time to progression
and to increase survival in women with breast cancer.
Prescribing Information
Important Safety Information
Online Privacy Policy
Home • About FARESTON® • Living
With Breast Cancer • Support Groups • Contact Us
FARESTON® is a registered trademark in the U.S. of GTx, Inc.
© 2006 GTx, Inc. Memphis, TN 38163
While GTx, Inc. makes reasonable efforts to include accurate, up-to-date information on this site, GTx, Inc. makes no warranties or representations as to its accuracy. GTx, Inc. assumes no liability for any errors or omissions in the content of this site.
|